FDA Draft Guidance Details Considerations for Rescinding Breakthrough Designation for Drugs
- June 24, 2022
The Food and Drug Administration (FDA) has issued draft guidance that details the circumstances that could prompt the agency to rescind a drug product’s breakthrough therapy designation.
ARTICLE TAGS
You must be logged in to access this content.